Acquired Company

Alfasigma completed the acquisition of Intercept Pharmaceuticals, Inc. for $19.00 per share in cash, with the completion announced on November 8, 2023.

Acquired by Alfasigma S.p.A. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. Show more

www.interceptpharma.com

Pharmaceutical Preparation Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$19.00

Open

$19.00

Volume

N/A

Day Range

$19.00 - $19.00

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

3.13%

Institutional Own.

81.30%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OCALIVA® (obeticholic acid) Details Primary biliary cholangitis, Infectious disease, COVID-19, Liver disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ocaliva + Bezafibrate Details Primary biliary cholangitis, Liver disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INT-787 Details Liver disease, Alcoholic hepatitis	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ocaliva Details Non-alcoholic steatohepatitis , Liver disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ocaliva Details Primary sclerosing cholangitis, Liver disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ocaliva Details Non-alcoholic steatohepatitis , Liver disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.